Kuros Biosciences Ltd. (CSBTF)
OTHER OTC:CSBTF
CSBTF Stock Chart & Stats
$35.00
$0.26(0.95%)
At close: 4:00 PM EST
$35.00
$0.26(0.95%)
Day’s Range― - ―
52-Week Range$21.00 - $42.81
Previous CloseN/A
Volume4.47K
Average Volume (3M)469.00
Market Cap
$1.21B
Enterprise Value$972.46M
Total Cash (Recent Filing)$15.66M
Total Debt (Recent Filing)$3.94M
Price to Earnings (P/E)498.6
Beta0.51
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.12
Shares Outstanding39,253,124
10 Day Avg. Volume795
30 Day Avg. Volume469
Financial Highlights & Ratios
PEG Ratio-3.21
Price to Book (P/B)15.78
Price to Sales (P/S)8.71
P/FCF Ratio-439.50
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue7.51
Enterprise Value/Gross Profit8.63
Enterprise Value/Ebitda95.37
Forecast
1Y Price Target
$48.10Price Target Upside37.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.5
Revenue Forecast (FY)$287.77M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Profitability InflectionConsistently high gross margins (~86% in 2025) and a profitability inflection in 2025 reflect strong unit economics. Durable margins provide pricing flexibility and operating leverage as sales scale, supporting reinvestment and reducing reliance on external funding if sustained.
Sustained Multi-year Revenue ScalingRevenue growth from ~4.0m in 2020 to ~121.3m in 2025 demonstrates sustained market adoption and scalable commercial execution. Multi-year scaling suggests durable demand for MagnetOs, enabling operating leverage and a clearer pathway to margin expansion as volumes rise.
Conservative Balance Sheet With Low LeverageA low debt-to-equity ratio (~0.06) and growing asset base indicate conservative financing and financial flexibility. Low leverage reduces refinancing and interest-rate risk, giving management room to fund commercial expansion or weather operational setbacks without immediate pressure to raise capital.
Bears Say
Weak Cash Generation / Cash ConversionOperating cash flow turned slightly negative (~-0.38m) and free cash flow meaningfully negative (~-2.4m) in 2025 despite accounting profit. This cash conversion gap raises near-term funding sensitivity and could necessitate dilution, additional borrowing, or curtailed investment if the trend persists.
Thin, Nascent ProfitabilityProfitability is nascent and thin (EBIT ~6.0%, net ~1.7%), leaving limited cushion against margin pressure. Small profits increase vulnerability to reimbursement shifts, pricing pressure, or input-cost inflation, making sustained earnings power dependent on continued volume growth and tight cost control.
Dependence On Hospital Adoption And ReimbursementRevenue depends heavily on hospital formulary access, surgeon adoption and reimbursement dynamics. These structural dependencies can slow geographic rollout, create uneven adoption across markets, and expose revenues to payer or policy shifts that reduce predictability of long-term growth.
Kuros Biosciences News
CSBTF FAQ
What was Kuros Biosciences Ltd.’s price range in the past 12 months?
Kuros Biosciences Ltd. lowest stock price was $21.00 and its highest was $42.81 in the past 12 months.
What is Kuros Biosciences Ltd.’s market cap?
Kuros Biosciences Ltd.’s market cap is $1.21B.
When is Kuros Biosciences Ltd.’s upcoming earnings report date?
Kuros Biosciences Ltd.’s upcoming earnings report date is Aug 12, 2026 which is in 120 days.
How were Kuros Biosciences Ltd.’s earnings last quarter?
Kuros Biosciences Ltd. released its earnings results on Mar 10, 2026. The company reported $0.119 earnings per share for the quarter, beating the consensus estimate of $0 by $0.119.
Is Kuros Biosciences Ltd. overvalued?
According to Wall Street analysts Kuros Biosciences Ltd.’s price is currently Undervalued.
Does Kuros Biosciences Ltd. pay dividends?
Kuros Biosciences Ltd. does not currently pay dividends.
What is Kuros Biosciences Ltd.’s EPS estimate?
Kuros Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kuros Biosciences Ltd. have?
Kuros Biosciences Ltd. has 39,253,124 shares outstanding.
What happened to Kuros Biosciences Ltd.’s price movement after its last earnings report?
Kuros Biosciences Ltd. reported an EPS of $0.119 in its last earnings report, beating expectations of $0. Following the earnings report the stock price went up 10.105%.
Which hedge fund is a major shareholder of Kuros Biosciences Ltd.?
Currently, no hedge funds are holding shares in CSBTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kuros Biosciences Ltd.
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.
CSBTF Company Deck
CSBTF Earnings Call
Q4 2026
0:00 / 0:00
CSBTF Stock 12 Month Forecast
Average Price Target
$48.10
▲(37.42% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Ownership Overview
―
Insiders
0.80% Mutual Funds
― Other Institutional Investors
97.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---